Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.

Oncotarget - 18 Oct 2016

Kim Seok Jin, Shin Hyun-Tae, Lee Hae-Ock, Kim Nayoung K D, Yun Jae Won, Hwang Jee Hyang, Kim Kihyun, Park Woong-Yang

Abstract excerpt

Clinically applicable platforms revealing actionable genomic alterations may improve the treatment efficacy of myeloma patients. In this pilot study, we used a high depth targeted sequencing panel containing 83 anti-cancer drug target genes to sequence genomic DNAs extracted from bone marrow aspirates of 23 patients with myeloma and 12 patients with amyloid light-chain (AL) amyloidosis. Mutation analysis revealed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Multiple Myeloma

Share to Pilot Projects

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27634910
DOI: 10.18632/oncotarget.12029
PMCID: PMC5356560

Genes

BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.PMID 27634910Read ↗

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.Semantic proximity Read ↗

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencingSemantic proximity Read ↗

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.Semantic proximity Read ↗

Mutational landscape reflects the biological continuum of plasma cell dyscrasias.Semantic proximity Read ↗

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Semantic proximity Read ↗

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.Semantic proximity Read ↗

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Semantic proximity Read ↗

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling moleculesSemantic proximity Read ↗

[Current state of genetic analysis in multiple myeloma and future perspectives].Semantic proximity Read ↗

Initial genome sequencing and analysis of multiple myeloma.Semantic proximity Read ↗

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathwaysSemantic proximity Read ↗

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.